Scarica l'app Stockscreener
6.36
5.22%
-0.35
Dopo l'orario di chiusura:
6.40
0.04
+0.63%
Personalis Inc Borsa (PSNL) Ultime notizie
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
Personalis to Participate in Upcoming Investor Events - BioSpace
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (NASDAQ: PSNL) director granted 6,250 RSUs and 37,500 options - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and 37,500-share stock option - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and options as board pay - Stock Titan
Personalis (PSNL) director Olivia Bloom granted RSUs and 37,500 options - Stock Titan
Personalis (PSNL) director receives 6,250 RSUs and 37,500 options - Stock Titan
Personalis Shares Rise on Medicare Coverage for Immunotherapy Monitoring - Moomoo
Personalis Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Personalis shareholders elect directors and approve proposals at annual meeting - Investing.com India
Lake Street Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $11 - Moomoo
Personalis (NASDAQ: PSNL) investors back directors, executive pay and BDO as auditor - Stock Titan
Expanded Medicare coverage for Personalis (NASDAQ: PSNL) NeXT Personal test - Stock Titan
Personalis Inc (NASDAQ: PSNL) Share Price, PSNL Stock News, PSNL Share Price & Updates - Kalkine
Personalis (PSNL) Q1 2026 Earnings Transcript - AOL.com
Personalis (PSNL) Expands Coverage for NeXT Personal MRD Test - GuruFocus
Why is Personalis stock surging today? By Investing.com - Investing.com Canada
Personalis receives Medicare coverage for Next Personal for immunotherapy monitoring across late-stage solid tumors - marketscreener.com
Personalis gains expanded Medicare coverage for cancer test - Investing.com
Personalis gains expanded Medicare coverage for cancer test By Investing.com - Investing.com UK
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
PSNL Maintained by Morgan Stanley -- Price Target Lowered to $9. - GuruFocus
Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026 - Stock Titan
PSNL: Directors and auditors elected, executive pay approved, with strong growth and AI focus - TradingView
Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating - Moomoo
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Cuts Target Price to $5.78 - Moomoo
PSNL Maintained by BTIG -- Price Target Lowered to $11.00 - GuruFocus
BTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
BTIG cuts Personalis stock price target on lab sector valuation - Investing.com
BTIG cuts Personalis stock price target on lab sector valuation By Investing.com - Investing.com Nigeria
Personalis, Inc. (NASDAQ:PSNL) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim Remains a Buy on Personalis (PSNL) - The Globe and Mail
Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Personalis Q1 Earnings Call Highlights - Barchart.com
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Q1 2026 Personalis Inc Earnings Call Transcript - GuruFocus
Guggenheim Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Needham reiterates Personalis stock rating citing MRD growth By Investing.com - Investing.com Australia
Personalis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham reiterates Personalis stock rating citing MRD growth - Investing.com UK
Personalis, Inc. (PSNL) Stock Analysis: Navigating a Promising 88% Upside in Healthcare Genomics - DirectorsTalk Interviews
Personalis: Q1 Earnings Snapshot - theheraldreview.com
Personalis Reports First Quarter Results and Recent Highlights - BioSpace
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss - Investing.com
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss By Investing.com - Investing.com South Africa
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):